Biocompatible Nanoparticle Technology Unlocking Cancer Therapies & Rapid Diagnostics
Sona’s unique gold nanorods have the potential to power the next generation of lateral flow diagnostics and play a key role in the advancement of impactful scientific and medical applications
Available for Mac, Windows, Chrome, and iOS.
Trusted by global brands
Previous
Next
Technology
Sona Gold Nanorod ("GNR") Technology
Uniquely biocompatible.
Unlocking of in-vivo medical applications potential
Applications
Targeted Hyperthermia Therapy
Sona GNRs in targeted hyperthermia may create the
opportunity to treat cancer without doing significant harm to healthy cells.
Concussion Tests
Sona’s concussion screening test to be used at the scene of injury
Bovine Tuberculosis Tests
Early detection at low cost without the need for test-and-slaughter
Latest News Releases
- May 30, 2023
Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy (“THT”) for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. The device will be used in Sona’s development of THT to transfer energy by way of infrared light to Sona’s proprietary, biocompatible gold nanorods in tumors which will then convert the light energy into heat. The light device is being designed to fit in the auxiliary channel of the sigmoidoscopes and colonoscopes used by oncology gastroenterologists.
Market Coverage Report
Report by:
Dated:
Varius nisi aliquet at nisi augue tempus. Eu vitae maecenas tellus varius quis pretium. Amet nibh venenatis nunc feugiat lectus.
Insights, Events and Media
Enim, justo, sed etiam lacus, nibh pellentesque ante sem vulputate. At etiam cursus adipiscing viverra dui.